% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:1037621,
      author       = {Galldiks, Norbert and Lohmann, Philipp and Friedrich,
                      Michel and Werner, Jan-Michael and Stetter, Isabelle and
                      Wollring, Michael M and Ceccon, Garry and Stegmayr, Carina
                      and Krause, Sandra and Fink, Gereon R and Law, Ian and
                      Langen, Karl-Josef and Tonn, Joerg-Christian},
      title        = {{PET} imaging of gliomas: {S}tatus quo and quo vadis?},
      journal      = {Neuro-Oncology},
      volume       = {26},
      number       = {$Supplement_9$},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2025-00792},
      pages        = {S185 - S198},
      year         = {2024},
      abstract     = {PET imaging, particularly using amino acid tracers, has
                      become a valuable adjunct to anatomical MRI in the clinical
                      management of patients with glioma. Collaborative
                      international efforts have led to the development of
                      clinical and technical guidelines for PET imaging in
                      gliomas. The increasing readiness of statutory health
                      insurance agencies, especially in European countries, to
                      reimburse amino acid PET underscores its growing importance
                      in clinical practice. Integrating artificial intelligence
                      and radiomics in PET imaging of patients with glioma may
                      significantly improve tumor detection, segmentation, and
                      response assessment. Efforts are ongoing to facilitate the
                      clinical translation of these techniques. Considerable
                      progress in computer technology developments (eg quantum
                      computers) may be helpful to accelerate these efforts.
                      Next-generation PET scanners, such as long-axial
                      field-of-view PET/CT scanners, have improved image quality
                      and body coverage and therefore expanded the spectrum of
                      indications for PET imaging in Neuro-Oncology (eg PET
                      imaging of the whole spine). Encouraging results of clinical
                      trials in patients with glioma have prompted the development
                      of PET tracers directing therapeutically relevant targets
                      (eg the mutant isocitrate dehydrogenase) for novel
                      anticancer agents in gliomas to improve response assessment.
                      In addition, the success of theranostics for the treatment
                      of extracranial neoplasms such as neuroendocrine tumors and
                      prostate cancer has currently prompted efforts to translate
                      this approach to patients with glioma. These advancements
                      highlight the evolving role of PET imaging in
                      Neuro-Oncology, offering insights into tumor biology and
                      treatment response, thereby informing personalized patient
                      care. Nevertheless, these innovations warrant further
                      validation in the near future.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {38970818},
      UT           = {WOS:001263250000001},
      doi          = {10.1093/neuonc/noae078},
      url          = {https://juser.fz-juelich.de/record/1037621},
}